亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Auristatin Tyramine Phosphate Prodrugs and Aminoquinoline Derivatives

标题
Auristatin Tyramine Phosphate Salts and Auristatin Aminoquinoline Derivatives and Prodrugs Thereof
详细技术说明
The remarkable anticancer properties of dolastatin 10, isolated from the sea hare (sea slug) Dolabella auricularia, have led to interest in closely related derivatives (auristatins) suitable for clinical trials. Most recently, such auristatins have been linked to antibodies for delivery. In many indications, however, it would be desirable to deliver such drugs without resort to conjugation. Researchers at Arizona State University have developed prodrug forms of a novel auristatin tyramine derivative as phosphate salts, as well as auristatin quinoline modifications. These compounds exhibit superior inhibition of cancer cell growth. In addition, auristatin TP sodium salt is water soluble, and is thus expected to have greater bioavailability. Existing auristatin drugs (e.g., SGN-35) are showing promise in clinical trials. The above novel compounds may have important advantages over such existing auristatin drugs and may prove to be important drugs for treating cancer. Potential Applications Inhibiting cancer cell growth Treating many types of cancer Benefits and Advantages Novel compounds displayed very strong cancer cell growth inhibition against a panel of murine and human cancer cell lines Auristatin TP sodium salt: Water soluble No need for conjugation to a macromolecule, such as an antibody, for delivery Likely greater bioavailability than other forms of the drug Auristatins 2-AQ and 6-AQ Aminoquinoline modifications of dolastatin 10 Various biological activities have been reported for simple derivatives of aminoquinolines, and these moieties are expected to confer distinct activity Suitable for attachment to an antibody For more information about the inventor(s) and their research, please see Dr. Pettit's departmental webpage
*Abstract
None
*IP Issue Date
Jun 2, 2015
*Principal Investigation

Name: George (bob) Pettit, Regents' Professor -FY18

Department: CLAS - Molecular Sciences -FY18


Name: Fiona Hogan, Non-ASU -FY18

Department: Non-ASU -FY18


Name: Steven Toms, Non-ASU -FY18

Department: Non-ASU -FY18

申请日期
Mar 29, 2012
申请号码
9,044,518
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备